Companies › Verdiva Bio Dev
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VRB-101 (Ecnoglutide) GLP-1 receptor agonist | GLP1R | Phase 2 | Obesity | Mar 2028 |
| VRB-103 | – | Phase 1 | Obesity | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07553299 | VRB-101 (Ecnoglutide) | Phase 2 | Obesity | Metabolic and endocrine | Sep 2026 |
| NCT07628127 | VRB-103 | Phase 1 | Obesity | Metabolic and endocrine | Mar 2028 |
| NCT07628127 | VRB-101 (Ecnoglutide) | Phase 1 | Obesity | Metabolic and endocrine | Mar 2028 |
Beijing Dongfang Biotech PolTREG Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.